Magnetic lipid nanoprobe platform to quickly and cheaply isolate extracellular vesicles from body fluids
Official title: Magnetic Lipid Nanoprobe Platform for Rapid, Highly-Efficient, and Cost-Effective Isolation of Extracellular Vesicles from Non-Invasive Bodily Fluids
Funded at Captis Diagnostics · NIH-11300972 · Data updated 2026-11-12
A new magnetic lipid nanoprobe system aims to rapidly and affordably pull extracellular vesicles from common body fluids to aid disease diagnosis.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Captis Diagnostics NIH-funded |
| Lab location | 1 site (Pittsburgh, UNITED STATES) |
| Project start | March 11, 2025 |
| Project end | March 10, 2027 |
| Funding year | 2026 |
| Award (this year) | $1,117,056 |
| NIH project number | 5R44TR005339-02 |
| Project ID | NIH-11300972 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates include individuals needing non-invasive diagnostic options for cancer, cardiovascular disease, metabolic disorders, organ transplant monitoring, or pregnancy-related conditions.
✕Less likely to help
Patients requiring invasive tissue biopsies or those not producing detectable levels of extracellular vesicles may see limited benefit.
What this research studies
This project focuses on a novel lipid nanoprobe that can capture extracellular vesicles from fluids like blood, urine, and saliva using a fast, low-cost workflow. The approach combines magnetic separation with a proprietary lipid-based capture to improve yield and throughput. By enabling multi-omics analysis from non-invasively collected samples, it could make repeat testing more feasible for patients. The effort is designed to translate into a clinically practical tool that supports better diagnostic decisions.
Why it matters
Potential benefit: If successful, patients could receive faster, less invasive diagnostics using samples that are easy to obtain.
How similar studies have gone: Previous work in EV isolation shows promise, but this platform aims to deliver higher throughput and lower cost with a clinically friendly workflow.
Where this research is happening
-
Captis Diagnostics
Pittsburgh, United States Active
Researchers
- Principal investigator: He, Hongzhang — Captis Diagnostics
- Study coordinator: He, Hongzhang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.